Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

  1. Kong, A.
  2. Rea, D.
  3. Ahmed, S.
  4. Beck, J.T.
  5. López, R.L.
  6. Biganzoli, L.
  7. Armstrong, A.C.
  8. Aglietta, M.
  9. Alba, E.
  10. Campone, M.
  11. Schmitz, S.-F.H.
  12. Lefebvre, C.
  13. Akimov, M.
  14. Lee, S.-C.
Aldizkaria:
Oncotarget

ISSN: 1949-2553

Argitalpen urtea: 2016

Alea: 7

Zenbakia: 25

Orrialdeak: 37680-37692

Mota: Artikulua

DOI: 10.18632/ONCOTARGET.8974 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus